Texas Children’s has for the first time used a new enzyme replacement therapy called Kebilidi as a cure to AADC, a rare neurological disorder.

Denali Therapeutics has become the latest on a growing list of biotechs to experience an FDA review delay in recent months. | ...

Spruce Biosciences ($SPRB) is on one of the most dramatic runs in biotech this year. Shares have surged nearly 2,900% over ...

Shares of Spruce Biosciences, Inc. (NASDAQ: SPRB) are surging Monday after the biotech company shared an important regulatory ...

Tokyo-based Takeda Pharmaceuticals Co. this month completed a $170 million expansion and renovation project on its Thousand ...

The mucopolysaccharidosis (MPS) market is rapidly evolving due to rising demand for effective therapies to manage glycosaminoglycan buildup and improve patient quality of life. Enzyme Replacement ...

Please provide your email address to receive an email when new articles are posted on . Researchers analyzed 19 children with Pompe disease seen at a Texas-based children’s hospital.

Children with Hunter Syndrome lack a certain enzyme in their blood. The Food and Drug Administration just approved an enzyme-replacement therapy for these patients. It had its start at UNC Hospitals.

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The first test ...

Austin, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Enzyme Replacement Therapy Market Size & Trends: According to SNS Insider, The Enzyme Replacement Therapy Market was estimated at USD 11.27 billion in 2024 ...

Ottawa, Sept. 24, 2025 (GLOBE NEWSWIRE) -- The global enzyme replacement therapy market size was valued at USD 10.4 billion in 2024 and is predicted to hit around USD 24.71 billion by 2034, rising at ...